• Platform
  • Pipeline
    • Overview
    • Clinical Trial
  • Team
    • Leadership
    • Board of Directors
  • News
  • Careers

ASGCT News: Kelonia Lentiviral Particles May Solve In Vivo Delivery Hurdles for CAR T Cells

by rob@robmaguiredesigns.com | May 17, 2023 | News

BioCentury’s 2022 class of emerging companies

by rob@robmaguiredesigns.com | Feb 2, 2023 | News

Med City News: As Cell Therapy Gains Ground, Efforts Emerge to Improve CAR T-Manufacturing

by rob@robmaguiredesigns.com | Jan 26, 2023 | News

BioWorld: Keeping it simple: Kelonia raises a $50M series A 

by brian@orrbitt.com | May 2, 2022 | News

Kelonia: redirecting in vivo gene therapy

by brian@orrbitt.com | Apr 28, 2022 | News

Kelonia Scores $50M to Propel In Vivo Gene Delivery Platform

by brian@orrbitt.com | Apr 28, 2022 | News

« Older Entries
Next Entries »

Recent Posts

  • Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
  • Kelonia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KLN-1010, an in vivo BCMA CAR-T Therapy for Relapsed and Refractory Multiple Myeloma   
  • Kelonia Therapeutics Presents First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting  
  • Kelonia Therapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data from in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual Meeting
  • Kelonia Therapeutics Enters into Strategic Collaboration with Johnson & Johnson to Advance in vivo CAR-T Therapies

Recent Comments

No comments to show.

Genetic Medicines for Every Patient.

  • Platform
  • Pipeline
    • Overview
    • Clinical Trial
  • Team
    • Leadership
    • Board of Directors
  • News
  • Careers




© 2025 KELONIA THERAPEUTICS, INC. ALL RIGHTS RESERVED.
PRIVACY POLICY. TERMS OF USE